Patents by Inventor Jens-Kristian Slott JENSEN

Jens-Kristian Slott JENSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316142
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: May 31, 2024
    Publication date: September 26, 2024
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20220218782
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20220031801
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: March 12, 2021
    Publication date: February 3, 2022
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 10973870
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 13, 2021
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 10729739
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 4, 2020
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20200237854
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20170290879
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: January 13, 2017
    Publication date: October 12, 2017
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Patent number: 9579359
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: February 28, 2017
    Assignee: FERRING B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20140113870
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: December 24, 2013
    Publication date: April 24, 2014
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • Publication number: 20090203623
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: February 10, 2009
    Publication date: August 13, 2009
    Inventors: Tine Kold OLESEN, Bo-Eric PERSSON, Per CANTOR, Egbert A. van der MEULEN, Jens-Kristian Slott JENSEN